7
↑7
↓0
—0
Evidence suggests Psilocybin mayincreaseTherapeutic outcomes.
7 studies (7 claims)
Emerging evidence
Typical effective dose 25 (25–25) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| a single 25 mg oral dose of psilocybin | Increases - both groups having clinically significant benefits | all outcomes assessed | Human | medication discontinued and unmedicated at screening groups | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| Psilocybin-assisted therapy (PAT) | Increases - shows transformative promise | treatment outcomes | Human | patients with cancer-related demoralization and chronic pain | Not specified | A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. |
| psilocybin | Increases - led to | an improvement in functional outcomes | Human | a participant in a phase 2b clinical trial of psilocybin for treatment-resistant depression | Not specified | Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.cited 1× |
| psilocybin | No effect - interactions with medications from several psychiatric drug classes | pharmacodynamic, physiological, and subjective outcomes | Human | healthy adults | Not specified | Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.cited 32× |
| psilocybin | Increases - greater mediating effect for subjective effects mediating therapeutic outcomes | therapeutic outcomes | Human | patients with depression or SUD | Not available | Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.cited 2× |
| psilocybin | Increases - greater mediating effect | therapeutic outcomes | Human | patients with depression | Not available | Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.cited 2× |
| psilocybin | Increases - may benefit some patients | treatment outcomes | Human | patients including when other options have failed | Not specified | Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being. |